8-K: Immuneering Announces Promising Interim Data from Phase 2a Trials of IMM-1-104 and IMM-6-415

Immuneering Corporation reported positive interim results from its Phase 2a trials for IMM-1-104 in pancreatic cancer and initial data for IMM-6-415 in advanced solid tumors.

Summary

• Immuneering Corporation has released updated interim data from three Phase 2a arms of their ongoing Phase 1/2a clinical trial of IMM-1-104, and initial interim data from the Phase 1 portion of their ongoing Phase 1/2a clinical trial of IMM-6-415.
• In the IMM-1-104 trial, the combination with modified Gemcitabine/nab-Paclitaxel (mGnP) in first-line pancreatic cancer showed a disease control rate of 86% and an overall response rate of 43% in seven evaluable patients.
• The combination of IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer showed 100% target tumor shrinkage and disease control in four evaluable patients.
• IMM-1-104 monotherapy in second-line pancreatic cancer achieved disease control in 11 out of 21 evaluable patients, with one patient achieving a partial response.
• IMM-1-104 was generally well tolerated in all three arms of the trial.
• Initial data from the IMM-6-415 trial showed significant plasma concentrations and up to 77% inhibition of phosphorylated extracellular signal-regulated kinase (pERK) at higher dose levels.
• IMM-6-415 monotherapy was generally well tolerated at all tested dose levels, with no dose limiting toxicities or serious adverse events observed.
• Additional data from the Phase 2a portion of the IMM-1-104 trial is expected in the second quarter of 2025.
• The company plans to initiate additional Phase 2a arms of IMM-1-104 in combination with a BRAF inhibitor for melanoma and with checkpoint inhibitors for both melanoma and non-small cell lung cancer in 2025.

Sentiment

Score: 8

Explanation: The document presents very positive interim clinical trial results, with high disease control rates and good tolerability, suggesting a strong potential for the company's drug candidates. The planned expansion of trials further enhances the positive outlook.

Positives

• The IMM-1-104 combination with mGnP showed a high disease control rate of 86% and an overall response rate of 43% in first-line pancreatic cancer.
• The IMM-1-104 combination with mFFX demonstrated 100% target tumor shrinkage and disease control in all four patients.
• IMM-1-104 monotherapy showed promising disease control in second-line pancreatic cancer with 11 out of 21 patients achieving disease control.
• IMM-6-415 achieved significant plasma concentrations and up to 77% pERK inhibition, indicating good drug activity.
• Both IMM-1-104 and IMM-6-415 were generally well tolerated with mostly Grade 1 and 2 adverse events.

Negatives

• One patient in the IMM-1-104 with mGnP arm showed progressive disease.
• Some Grade 3 adverse events were observed in the IMM-1-104 with mGnP arm, including anemia, diarrhea, and neutrophil count decrease.
• Some Grade 2 adverse events were observed in the IMM-1-104 monotherapy arm, including rash, diarrhea, fatigue, and blurred vision.

Risks

• The results are based on interim data and may change as the trials progress.
• The sample sizes in some arms of the IMM-1-104 trial are small, which may limit the generalizability of the results.
• The development of oncology drugs is inherently risky, and there is no guarantee that these drugs will be approved or successful in larger trials.
• The company's future plans are subject to inherent uncertainties, risks and assumptions that are difficult to predict.

Future Outlook

The company plans to release additional data from the Phase 2a portion of the IMM-1-104 trial in the second quarter of 2025 and initiate additional Phase 2a arms of IMM-1-104 in combination with a BRAF inhibitor for melanoma and with checkpoint inhibitors for both melanoma and non-small cell lung cancer in 2025.

Industry Context

The announcement is significant in the context of the oncology drug development industry, where there is a high unmet need for effective treatments for advanced solid tumors, particularly those with RAS and RAF mutations. The positive interim results for IMM-1-104 and IMM-6-415 could position Immuneering as a key player in this space.

Comparison to Industry Standards

• The reported 43% overall response rate for IMM-1-104 with mGnP in first-line pancreatic cancer is promising when compared to historical response rates for standard chemotherapy regimens in this setting, which typically range from 20-30%.
• The 100% target tumor shrinkage and disease control observed in the IMM-1-104 with mFFX arm is exceptional and exceeds typical results seen with mFFX alone.
• The disease control rate of 11 out of 21 patients for IMM-1-104 monotherapy in second-line pancreatic cancer is encouraging, as second-line treatment options are often limited and less effective.
• The pERK inhibition of up to 77% observed with IMM-6-415 is a strong indicator of target engagement and potential efficacy, which is comparable to or better than some other targeted therapies in development for similar pathways.
• Companies like Amgen, with their KRAS inhibitor Lumakras, and Mirati Therapeutics, with their KRAS inhibitor Krazati, are developing targeted therapies for RAS-mutant cancers, and Immuneering's results with IMM-1-104 and IMM-6-415 suggest they are competitive in this space.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with advanced solid tumors may benefit from the development of these new therapies.
• Employees may be motivated by the positive progress of the company's drug candidates.

Next Steps

• The company expects to release additional data from the Phase 2a portion of the IMM-1-104 trial in the second quarter of 2025.
• The company plans to initiate additional Phase 2a arms of IMM-1-104 in combination with a BRAF inhibitor for melanoma and with checkpoint inhibitors for both melanoma and non-small cell lung cancer in 2025.

Key Dates

Keywords

IMM-1-104, IMM-6-415, Pancreatic Cancer, Solid Tumors, RAS mutations, RAF mutations, Clinical Trial, Phase 2a, Phase 1, Oncology, Drug Development, Disease Control Rate, Overall Response Rate, pERK inhibition